用于精准治疗性T细胞工程的新型基因外基因组安全港
研究提出并验证一种识别基因外基因组安全港(GSH)的算法,该算法基于7项标准以降低基因毒性、提高CRISPR/Cas9靶向效率并防止转基因沉默。在GSH6位点表达CD19 CAR的T细胞在小鼠急性淋巴细胞白血病模型中低细胞剂量即可治愈,效力与TRAC位点工程化的CAR T细胞相当,并在输注后100天有效抵抗肿瘤再攻击。
要点
- 基于7项标准的算法可识别基因外基因组安全港(GSH),用于高效DNA整合和稳定的CAR表达。
- GSH6满足全部7项标准,在该位点表达CD19 CAR的T细胞在小鼠ALL模型中低细胞剂量即可治愈。
- GSH6 CAR T细胞效力与TRAC位点工程化的CAR T细胞相当,输注后100天有效抵抗肿瘤再攻击。
核心结论
- 识别功能性基因外GSH扩展了可用于治疗性精准工程化的人类基因组范围。
研究设计与样本
- 研究报道并验证一种识别基因外基因组安全港(GSH)的算法,该算法基于7项标准。
- 在人外周血T细胞中靶向DNA整合并评估CAR表达的持续性和可预测性。
- 在小鼠急性淋巴细胞白血病模型中评估GSH6位点CD19 CAR T细胞的疗效。
主要发现
- GSH6满足全部7项标准。
- 在GSH6位点表达CD19 CAR的T细胞在小鼠急性淋巴细胞白血病模型中低细胞剂量即可治愈。
- GSH6 CAR T细胞效力与TRAC位点工程化的CAR T细胞相当。
- GSH6 CAR T细胞在输注后100天有效抵抗肿瘤再攻击。
关键数值与推荐
- 算法基于7项标准建立,旨在通过引导转基因整合远离功能重要的基因组元件来最小化基因毒性、最大化高效CRISPR/Cas9介导的靶向并避免转基因随时间沉默。
- GSH6满足全部7项标准。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cell therapies that rely on engineered immune cells can be enhanced by achieving uniform and controlled transgene expression in order to maximize T-cell function and achieve predictable patient responses. Although they are effective, current genetic engineering strategies that use γ-retroviral, lentiviral, and transposon-based vectors to integrate transgenes, unavoidably produce variegated transgene expression in addition to posing a risk of insertional mutagenesis. In the setting of chimeric antigen receptor (CAR) therapy, inconsistent and random CAR expression may result in tonic signaling, T-cell exhaustion, and variable T-cell persistence. Here, we report and validate an algorithm for the identification of extragenic genomic safe harbors (GSH) that can be efficiently targeted for DNA integration and can support sustained and predictable CAR expression in human peripheral blood T cells. The algorithm is based on 7 criteria established to minimize genotoxicity by directing transgene integration away from functionally important genomic elements, maximize efficient CRISPR/Cas9-mediated targeting, and avert transgene silencing over time. T cells engineered to express a CD19 CAR at GSH6, which meets all 7 criteria, are curative at low cell dose in a mouse model of acute lymphoblastic leukemia, matching the potency of CAR T cells engineered at the TRAC locus and effectively resisting tumor rechallenge 100 days after their infusion. The identification of functional extragenic GSHs thus expands the human genome available for therapeutic precision engineering.
引用
- Odak A, Yuan H, Feucht J, et al. Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering. Blood. 2023. PMID: 36745870. doi:10.1182/blood.2022018924
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。